Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP24A1 | Q07973 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | TBXAS1 | P24557 | 7/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.36 |
| ▸ | QPCT | Q16769 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | QPCTL | Q9NXS2 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.35 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.34 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14219626 | 0.85 | NFKB1 (0.39) | CYP24A1MAPTTBXAS1ALDH1A1NFKB1 | |
| SCHEMBL27397907 | 0.83 | CYP24A1 (0.38) | CYP24A1MAPTTBXAS1ALDH1A1NFKB1 | |
| SCHEMBL7789777 | 0.83 | CYP24A1 (0.38) | CYP24A1MAPTTBXAS1ALDH1A1NFKB1 | |
| SCHEMBL14219610 | 0.83 | CYP24A1 (0.38) | CYP24A1MAPTTBXAS1ALDH1A1NFKB1 | |
| SCHEMBL9610803 | 0.83 | CYP24A1 (0.38) | CYP24A1MAPTTBXAS1ALDH1A1NFKB1 | |
| SCHEMBL22160768 | 0.80 | CYP24A1 (0.37) | CYP24A1MAPTTBXAS1ALDH1A1NFKB1 | |
| SCHEMBL156615 | 0.78 | MAPT (0.37) | CYP24A1MAPTTBXAS1ALDH1A1NFKB1 | |
| SCHEMBL5314422 | 0.78 | ALDH1A1 (0.36) | CYP24A1MAPTTBXAS1ALDH1A1NFKB1 | |
| SCHEMBL13446154 | 0.78 | L3MBTL1 (0.40) | CYP24A1MAPTTBXAS1ALDH1A1HTT | |
| SCHEMBL3027719 | 0.75 | L3MBTL1 (0.38) | CYP24A1MAPTTBXAS1ALDH1A1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008082224-A1 | WATER-SOLUBLE PHOTOINITIATORS | INKTEC CO., LTD. (KR) | 2008-07-10 | — | — | WO | claimed |
| US-RE35558-E | (2R)-2-[di(2-propyl)phosphonyylmethoxy]-3-P-toluenesulfonyloxy-1-trimethylacetoxypropane, its preparation and use | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY OF THE ACADEMY OF SCIENCES OF THE CZECH REPUBLIC (CS) | 1997-07-08 | — | — | US | claimed |
| US-5130427-A | Viricides formed by etherification, esterification and reaction with a phosphonate containing compound | CESKOSLOVENSKA AKADEMIE VED (CS) | 1992-07-14 | — | — | US | claimed |
| EP-0470809-A1 | Antiviral nucleosides, compounds useful in their preparation and processes of making them | Ceskoslovenska akademie ved (CS) | 1992-02-12 | — | — | EP | claimed |
| JP-5230087-A | — | — | None | — | — | JP | disclosed |
| CN-119707784-A | Process for preparing amino acid derivatives | 株式会社API | 2025-03-28 | — | — | CN | disclosed |
| CN-112930338-B | Process for preparing amino acid derivatives | 株式会社API | 2024-12-24 | — | — | CN | disclosed |
| US-20240226113-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | KUMQUAT BIOSCIENCES INC. | 2024-07-11 | — | — | US | disclosed |
| US-12018003-B2 | Substituted pyrimidines as matrix metalloproteinase-9 hemopexin domain inhibitors | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2024-06-25 | — | — | US | disclosed |
| US-11857635-B2 | Linker compound, polyethylene glycol-linker conjugate and derivative thereof and polyethylene glycol-linker-drug conjugate | JENKEM TECHNOLOGY CO., LTD. (TIANJIN) (CN) | 2024-01-02 | — | — | US | disclosed |
| US-11638760-B2 | Pyrrolobenzodiazepine antibody conjugates | MERSANA THERAPEUTICS, INC. (US) | 2023-05-02 | — | — | US | disclosed |
| US-20230043447-A1 | PEPTIDE-CONTAINING LINKERS FOR ANTIBODY-DRUG CONJUGATES | MERSANA THERAPEUTICS, INC. | 2023-02-09 | — | — | US | disclosed |
| US-7335753-B2 | Bifunctional heterocyclic compounds and methods of making and using same | RIB-X PHARMACEUTICALS, INC. (US) | 2008-02-26 | — | — | US | disclosed |
| EP-1888612-A1 | CRYSTALLINE SUGAR COMPOSITIONS AND METHOD OF MAKING | Amicus Therapeutics, Inc. (US) | 2008-02-20 | — | — | EP | disclosed |
| US-20060293250-A1 | Crystalline sugar compositions and method of making | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2006-12-28 | — | — | US | disclosed |
| WO-2006133447-A1 | CRYSTALLINE SUGAR COMPOSITIONS AND METHOD OF MAKING | AMICUS THERAPEUTICS, INC. (US) | 2006-12-14 | — | — | WO | disclosed |
| US-RE35558-E | (2R)-2-[di(2-propyl)phosphonyylmethoxy]-3-P-toluenesulfonyloxy-1-trimethylacetoxypropane, its preparation and use | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY OF THE ACADEMY OF SCIENCES OF THE CZECH REPUBLIC (CS) | 1997-07-08 | — | — | US | disclosed |
| JP-H05230087-A | (2R)-2-(DI(2-PROPYL)PHOSPHONYLMETHOXY)-3-P-TOLUENESULFONYLOXY-1-TRIMETHYLACETOXYPROPANE, ITS PREPARATION AND UTILIZATION | CESKOSLOVENSKA AKAD VED | 1993-09-07 | — | — | JP | disclosed |
| US-5130427-A | Viricides formed by etherification, esterification and reaction with a phosphonate containing compound | CESKOSLOVENSKA AKADEMIE VED (CS) | 1992-07-14 | — | — | US | disclosed |
| EP-0470809-A1 | Antiviral nucleosides, compounds useful in their preparation and processes of making them | Ceskoslovenska akademie ved (CS) | 1992-02-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060293250-A1 | Crystalline sugar compositions and method of making | MGAM, DAD1, UGDH | CYP24A1 2421/4885MAPT 1282/4885TBXAS1 2303/4885 |
| US-12018003-B2 | Substituted pyrimidines as matrix metalloproteinase-9 hemopexin domain inhibitors | MMP9, MMP7, MMP11 | CYP24A1 2299/4885MAPT 422/4885TBXAS1 219/4885 |
| US-20240226113-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | TP53, HRAS, KRAS | CYP24A1 4669/4885MAPT 2968/4885TBXAS1 1662/4885 |
| US-20230043447-A1 | PEPTIDE-CONTAINING LINKERS FOR ANTIBODY-DRUG CONJUGATES | CD2BP2, DNPEP, LNPEP | CYP24A1 4212/4885MAPT 634/4885TBXAS1 4053/4885 |
| US-11638760-B2 | Pyrrolobenzodiazepine antibody conjugates | GABRA4, GABRA1, GABRA2 | CYP24A1 1667/4885MAPT 585/4885TBXAS1 3361/4885 |
| US-11857635-B2 | Linker compound, polyethylene glycol-linker conjugate and derivative thereof and polyethylene glycol-linker-drug conjugate | DCLRE1A, LANCL2, SI | CYP24A1 2226/4885MAPT 1039/4885TBXAS1 4021/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.